{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Non-Hodgkin%3B+Leukemia%2C+Chronic+Lymphocytic&page=18", "query": { "condition": "Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 937, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Non-Hodgkin%3B+Leukemia%2C+Chronic+Lymphocytic&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma%2C+Non-Hodgkin%3B+Leukemia%2C+Chronic+Lymphocytic&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:38:17.345Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04666038", "title": "Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2021-03-09", "completion_date": "2027-05", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 46, "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 41 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666038" }, { "nct_id": "NCT07711327", "title": "Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation (AF)", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Tina Baykaner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2026-08", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 3, "location_summary": "Duarte, California • San Diego, California • Stanford, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07711327" }, { "nct_id": "NCT00010283", "title": "Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Graft Versus Host Disease", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "beclomethasone dipropionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "5 Years to 75 Years" }, "enrollment_count": null, "start_date": "2000-07", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00010283" }, { "nct_id": "NCT03153202", "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joshua Brody", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 23, "start_date": "2017-07-14", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153202" }, { "nct_id": "NCT00089141", "title": "Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Martin, Paul", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 151, "start_date": "2004-05", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 15, "location_summary": "Duarte, California • Stanford, California • Gainesville, Florida + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089141" }, { "nct_id": "NCT00993694", "title": "Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Methemoglobinemia", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "dapsone", "type": "DRUG" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 41, "start_date": "2009-01", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00993694" }, { "nct_id": "NCT03333486", "title": "Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Leukemia in Remission", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With Gene Mutations", "Aplastic Anemia", "B-Cell Non-Hodgkin Lymphoma", "CD40 Ligand Deficiency", "Chronic Granulomatous Disease", "Chronic Leukemia in Remission", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Congenital Amegakaryocytic Thrombocytopenia", "Congenital Neutropenia", "Congenital Pure Red Cell Aplasia", "Glanzmann Thrombasthenia", "Immunodeficiency Syndrome", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Plasma Cell Myeloma", "Polycythemia Vera", "Recurrent Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Severe Aplastic Anemia", "Shwachman-Diamond Syndrome", "Sickle Cell Disease", "T-Cell Non-Hodgkin Lymphoma", "Thalassemia", "Waldenstrom Macroglobulinemia", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 31, "start_date": "2017-12-07", "completion_date": "2023-08-28", "has_results": true, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333486" }, { "nct_id": "NCT00849654", "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "B-Cell Leukemia" ], "interventions": [ { "name": "PCI-32765", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2009-02", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-05-22", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 9, "location_summary": "Palo Alto, California • Chicago, Illinois • Bethesda, Maryland + 6 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849654" }, { "nct_id": "NCT00626496", "title": "Family Study of Lymphoproliferative Disorders", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, B-Cell", "Monoclonal B-Cell Lymphocytosis", "Multiple Myeloma" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 3000, "start_date": "2004-04-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00626496" }, { "nct_id": "NCT02661035", "title": "Allo HSCT Using RIC for Hematological Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myelodysplastic Syndromes", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B-Cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-Cell Lymphoma", "Prolymphocytic Leukemia", "Lymphoblastic Lymphoma", "Burkitt's Lymphoma", "Non-Hodgkin's Lymphoma", "Multiple Myeloma", "Myeloproliferative Syndromes", "Hematological Diseases" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" }, { "name": "TBI", "type": "RADIATION" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cells", "type": "BIOLOGICAL" }, { "name": "Related or Unrelated Bone Marrow Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 156, "start_date": "2017-03-09", "completion_date": "2023-05-29", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-14T11:38:17.345Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02661035" } ] }